Piggyback toric IOL effective for astigmatism

Article

Implanting a customized primary or a secondary piggyback toric IOL post-penetrating keratoplasty (PK) is effective for astigmatism, claims a paper in Eye.

Implanting a customized primary or a secondary piggyback toric IOL post-penetrating keratoplasty (PK) is effective for astigmatism, claims a paper in Eye.

Dr S. Srinivasan et al., Department of Ophthalmology, University Hospital Ayr, Ayr, Scotland, UK, conducted a prospective case series on nine eyes of nine patients with post-PK astigmatism.

Of the patients assessed, six underwent simultaneous phacoemulsification (PE) and three pseudophakic eyes received a secondary 'piggyback' toric IOL implanted in the ciliary sulcus. Outcome measures included Pre- and postoperative uncorrected (UDVA) and best-corrected (BDVA) distance visual acuities and refractive errors.

Change in magnitude of astigmatism pre- and postoperatively were calculated by Cartesian astigmatic vectors. Preoperative and postoperative endothelial cell counts were also assessed.

Preoperative UDVA improved from 1.13±0.51 logMAR to 0.48±0.24 postoperatively. BDVA findings did not present any significant changes from 0.31±0.27 to 0.26±0.19. Preoperative and postoperative refractive cylinder was 0.83±1.09 D and 3.89±4.01 D, respectively.

Astigmatic Cartesian x and y coordinates were significantly reduced and mean endothelial cell loss was 9.9%. Both implantation of a customized primary IOL or a secondary piggyback toric IOL were effective modalities for treating patients with high post-PK astigmatism.

To read the abstract please visit the journal here.

Recent Videos
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
Stefano Mercuri, MD, first author of the winning eposter “Genotype-phenotype correlations in a cohort of genetically determined Retinitis Pigmentosa (RP) Italian patients with Rho gene mutations”
Bahram Bodaghi, MD, PHD, FEBO at the 2024 EURETINA meeting
Enrico Borrelli, MD, FEBO, speaks at EURETINA
Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.
© 2024 MJH Life Sciences

All rights reserved.